Overall, the level of NTNG1 was higher in cisplatin-resistant ovarian cancer tissues compared with cisplatin-sensitive ones; patients with a high NTNG1 level in cancer tissues had shorter PFS and PFI. This evidence concerns the gene NTNG1 and ovarian cancer.